Last reviewed 2026-05-14 · How we verify

IVW-1001 Ophthalmic Eyelid Wipe 0.4%

IVIEW Therapeutics Inc. · Phase 2 active Small molecule

IVW-1001 Ophthalmic Eyelid Wipe 0.4% is a Small molecule drug developed by IVIEW Therapeutics Inc.. It is currently in Phase 2 development.

At a glance

Generic name	IVW-1001 Ophthalmic Eyelid Wipe 0.4%
Sponsor	IVIEW Therapeutics Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase 2b Controlled Study of Dosing Techniques - Part B (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

IVW-1001 Ophthalmic Eyelid Wipe 0.4% CI brief — competitive landscape report
IVW-1001 Ophthalmic Eyelid Wipe 0.4% updates RSS · CI watch RSS
IVIEW Therapeutics Inc. portfolio CI

Frequently asked questions about IVW-1001 Ophthalmic Eyelid Wipe 0.4%

What is IVW-1001 Ophthalmic Eyelid Wipe 0.4%?

IVW-1001 Ophthalmic Eyelid Wipe 0.4% is a Small molecule drug developed by IVIEW Therapeutics Inc..

Who makes IVW-1001 Ophthalmic Eyelid Wipe 0.4%?

IVW-1001 Ophthalmic Eyelid Wipe 0.4% is developed by IVIEW Therapeutics Inc. (see full IVIEW Therapeutics Inc. pipeline at /company/iview-therapeutics-inc).

What development phase is IVW-1001 Ophthalmic Eyelid Wipe 0.4% in?

IVW-1001 Ophthalmic Eyelid Wipe 0.4% is in Phase 2.

Manufacturer: IVIEW Therapeutics Inc. — full pipeline
Compare: IVW-1001 Ophthalmic Eyelid Wipe 0.4% vs similar drugs
Pricing: IVW-1001 Ophthalmic Eyelid Wipe 0.4% cost, discount & access